CNS and inflammation by Tomoum, Hoda Y
Egypt J Pediatr Allergy Immunol 2007; 5(1): 3-9. 
3 
CNS and inflammation 
 
Hoda Y. Tomoum 
Associate Professor of Pediatrics, Ain Shams University, Cairo. 
 
CNS immune privilege (or not?) 
The central nervous system (CNS) immune 
privilege is an experimentally defined phenomenon. 
Tissues that are rapidly rejected by the immune 
system when grafted in sites, such as the skin, show 
prolonged survival when grafted into the CNS. 
Initially, CNS immune privilege was construed as 
CNS isolation from the immune system by the 
blood-brain barrier (BBB), the lack of draining 
lymphatics, and the apparent immunoincompetence 
of microglia, the resident CNS macrophage1. 
Moreover, except for astrocytes, there is no 
constitutive expression of MHC molecules in the 
cells of the CNS. The most convincing evidence of 
all is that tissue transplanted from one individual 
into the brain of another individual survives for 
extended periods of time2. The 'immune privilege' 
of the CNS is indispensable for damage limitation 
during inflammation in a sensitive organ with poor 
regenerative capacity. It is a longstanding notion 
which, over time, has acquired several 
misconceptions and a lack of precision in its 
definition3. 
There is no doubt that the brain differs 
significantly from other tissues in its responses to 
pathogenic challenges. Infection or inflammation 
elicits rather different responses in the brain to 
those in other tissues. This is most evident in 
leukocyte recruitment, which is rapid in many 
systemic organs, but modest and delayed in the 
brain. In spite of these notable differences, the brain 
does exhibit key features of inflammation (Table 
1)4. 
 
 
Table 1. Key features of CNS inflammation4. 
 
Glial activation 
Oedema 
MHC expression 
Systemic acute phase response with general 
inflammation and acute phase protein synthesis 
Complement activation – e.g. anaphylatoxins, membrane 
attack complex 
Synthesis of inflammatory mediators – e.g. cytokines, 
free radicals, prostaglandins 
Expression of adhesion molecules 
Invasion of immune cells 
 
 
 
Leukocytes have the ability to infiltrate the 
CNS and cytokines are produced by resident cells, 
especially during injuries and diseases. Although 
the cellular source and role of these immune ligands 
are better known, their exact contribution to brain 
protection, repair or diseases still remains highly 
debated today. It is now generally accepted that 
microglia play a central role in this response, at 
least for the production of cytokines participating in 
the innate immune system. Cytokines can also cross 
the BBB, either by active transport or through leaky 
regions of endothelia when the BBB is 
compromised by a pathological condition. Thus the 
CNS can be affected not only by inflammatory 
mediators produced within the brain, but also 
through the actions of mediators originating from 
the periphery5-7. 
Innate immunity and inflammation are also 
controlled by the vagus nerve, previously known as 
a regulator of other vital physiological functions. 
Activation of vagus nerve cholinergic signalling 
inhibits TNF (tumour necrosis factor) and other 
pro-inflammatory cytokine overproduction through 
'immune' alpha7 nicotinic receptor-mediated 
mechanisms. This efferent vagus nerve-based 
'cholinergic anti-inflammatory pathway' has been 
elucidated as a critical regulator of inflammation in 
several experimental models of disease. Advances 
in understanding the receptor and molecular 
mechanisms of cholinergic anti-inflammatory 
signalling indicate that selective alpha7 nicotinic 
receptor agonists and centrally acting cholinergic 
enhancers can be used in the treatment of 
pathological conditions characterized by cytokine 
overproduction8. 
The most intense interest in inflammation in the 
CNS has arisen from its potential role in diseases 
including acute brain injury, stroke, epilepsy, 
multiple sclerosis, motor neurone disease, 
movement disorders, and more recently some 
psychiatric disorders such as depression, anxiety 
and schizophrenia. 
 
Stroke and cerebral ischaemia 
A growing number of recent investigations have 
established a critical role for leukocytes in 
propagating tissue damage after ischemia and 
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reperfusion in stroke. Inflammatory interactions 
that occur at the blood-endothelium interface, 
involving cytokines, adhesion molecules, 
chemokines and leukocytes, are critical to the 
pathogenesis of tissue damage in cerebral 
infarction9. 
Cytokines in ischemic injury 
It has been reported that transient forebrain 
ischemia in animal model was associated with 
induction of interleukin (IL)-1β mRNA10, IL-6 
mRNA11, TNFα12, and transforming growth factor β 
(TGF-β)13, and that focal cerebral ischemia caused 
by middle cerebral artery occlusion (MCAO) 
induces the mRNA expression for IL-614, IL-1015, 
granulocyte colony-stimulating factor (G-CSF)16, 
TNFα17, TGFβ18, and erythropoietin (EPO)19. 
By using recombinant cytokines or their 
receptor antagonists, neutralizing antibodies or gene 
manipulation techniques, the role of cytokines in 
ischemic brain has been examined. Neutralizing 
antibody against IL-1β20 and IL-1 receptor 
antagonist21 were reported to attenuate brain 
infarction. This idea was supported by the studies 
using gene manipulation techniques. IL-1α/IL-1β 
double knockout mice exhibited reduced ischemic 
infarct volumes compared with wild type ones after 
the transient MCAO22. Both intracerebroventricular 
and systemic injection of the anti-inflammatory 
cytokine IL-10 decreased the infarct volume23, 
suggesting that an anti-inflammatory therapy using 
IL-10 can provide neuroprotection in ischemic 
stroke. In addition to these cytokines, G-CSF has 
also been shown to exhibit a significant 
neuroprotective effect in the rat transient MCAO 
model24. 
Chemokines in ischemic injury 
Enhanced expression of mRNAs for monocyte 
chemoattractant protein-1 (MCP-1, CCL2), and 
macrophage inflammatory protein-1α (MIP-1α, 
CCL3)25-26 was demonstrated in the ischemic brain 
using a rat MCAO model. Increase in the peptide 
contents of MCP-1 /CCL2 has been also shown in 
the brain after the ischemic insult27. Broad-spectrum 
chemokine antagonists have been reported to 
decrease the infarct volume in rat28. A 
neuroprotective effect of a small molecule 
antagonist against CCR2/CCR5 chemokine 
receptors has also been reported29. 
The mechanism underlying the harmful (or 
protective) effect of cytokines/chemokines in the 
ischemic brain remains to be elucidated. One 
possible site for the action of brain 
cytokines/chemokines is glial cells such as 
astrocytes and microglia, which express several 
types of cytokine/chemokine receptors. Another site 
of action of brain cytokines/chemokines may be the 
vascular endothelium30. The roles of cytokines and 
chemokines as mediators for neuro-glio-vascular 
interaction in the ischemic brain are schematically 
illustrated in Figure 1. 
 
Brain trauma 
Traumatic brain injury (TBI) is a major cause of 
mortality in young people, and triggers an 
inflammatory response that is initiated by the 
release of proinflammatory cytokines. Both mRNA 
and proteins of cortical IL-1α and IL-1β31, as well 
as IL-6 and TNFα mRNA expression32 were 
increased after induced traumatic brain injury in 
adult rats.  
IL-1 contributes directly to experimentally-
induced traumatic brain injury. The mechanisms of 
action of IL-1 are largely unknown, but may 
involve effects on glia, endothelia, and neurones, or 
on physical parameters within the brain such as 
temperature or acidity33. Agents that inhibit TNF 
improve both short- and long-term neurological 
outcome in rats, and IL-6 may be neuroprotective 
since significant correlation was detected between 
peak IL-6 levels and Glasgow outcome scores in 
injured patients. It seems to be an endogenous 
neuroprotective cytokine produced in response to 
severe head trauma34. 
 
PANDAS 
In the 1980s, an outbreak of Group A streptococcal 
tonsillitis in Rhode Island was associated with a 10-
fold increase in the incidence of motor tics (without 
chorea); the concept of post-streptococcal tics was 
born. Subsequent identification of further patients 
led to the development of a new acronym: 
PANDAS (paediatric autoimmune neuropsychiatric 
disorders associated with streptococcal 
infections)35. 
PANDAS was defined as post-streptococcal 
emergence of obsessive compulsive disorders 
(OCD) and/or tics; however, analysis of 50 patients 
with PANDAS demonstrated a high incidence of 
other emotional disorders (major depression 36%, 
separation anxiety 20%), conduct disorders 
(oppositional defiant disorder 40%) and attention 
deficit hyperactivity disorder (ADHD) (40%)36. A 
recent epidemiological community study of 1596 
children reported 339 with a history of tics, often 
associated with co-morbid OCD and ADHD37. If 
the association with streptococcus is correct, 
collectively these disorders may prove to be the 
commonest form of autoimmune disease. 
The immunopathogenesis of post-streptococcal 
CNS syndromes is incompletely understood. Most 
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of the investigations to date have focused on anti-
neuronal antibodies as the possible mediators. 
However, alternative immune mechanisms are 
possible including cytotoxic T-lymphocyte attack, 
cytokine-mediated neuronal dysfunction and even 
superantigen-mediated Immunity38.  
 
Epilepsy 
Seizures are caused by abnormal, high-frequency 
discharge of groups of neurones. The underlying 
neurochemical mechanisms are unknown, although 
increasing evidence implicates proinflammatory 
cytokines. IL-1 receptor type I knockout animals 
exhibited enhanced resistance to seizures induced 
by bicuculline39. Furthermore, intrahippocampal 
injection of recombinant IL-1β in normal animals 
enhanced the severity of seizures provoked by both 
bicuculline39 and kainic acid40 and selective 
blocking of caspase-1, which in turn reduces the 
brain availability of IL-1β, provided an effective 
anticonvulsive effect in experimental studies41. 
A possible mechanism by which IL-1 receptor 
type I activation leads to seizure involves increased 
phosphorylation of the NR2A/B subunit of N-
methyl-d-aspartate receptor through activation of 
tyrosine kinases, which results in N-methyl-d-
aspartate receptor-mediated Ca2+ influx42. Thus, 
cytokines would appear to be endogenous 
proconvulsant factors that contribute to seizures of 
various origins, including febrile convulsions. On 
the other hand, a recent study demonstrated 
experimental evidence of a protective anti-
inflammatory role for IL-10 in epileptiform events 
which are induced by brief episodes of hypoxia in 
rat hippocampus43. 
 
Multiple sclerosis 
Multiple sclerosis (MS) is a complex genetic 
disease characterized by inflammation in the CNS 
white matter mediated by activated autoreactive 
lymphocytes. Invasion of the CNS by T cells and 
macrophages leads to damage to the myelin sheaths 
surrounding axons, loss of neuronal function and 
neuronal death. Characteristically, the disease 
progresses in cycles of relapse, often associated 
with systemic infection and inflammation, and/or 
remission44.  
Many inflammatory mediators are upregulated 
in MS and associated with the demyelinating 
lesions45. Increases in T cell IFN-γ and IL-12 
secretion46 and increase in IL-12p40 mRNA with 
decreases in IL-10 mRNA expression47 have been 
observed. Investigators have even demonstrated 
striking defects in the induction of Tr1 type of 
regulatory T cells with CD46 costimulation as 
measured by IL-10 but not IFN-γ secretion in 
patients with MS as compared to healthy subjects. 
This loss of Tr1 cell-associated IL-10 secretion was 
specific to CD46 and not CD28 costimulation and 
was associated with an altered regulation of the 
CD46-Cy2 isoform that differentially regulates T 
cell function in a CD46-transgenic murine model. 
These data demonstrate a second major regulatory 
T cell (Treg) defect in human autoimmune disease 
associated with the CD46 pathway48. 
 
Other chronic conditions 
Inflammation undoubtedly contributes to other 
chronic CNS disorders. There is mounting evidence 
that chronic inflammatory processes play a 
fundamental role in the progression of 
neuropathological changes of Alzheimer's disease. 
It has been shown, that a reciprocal relationship 
exists between the local inflammation and senile 
plaques and neurofibrillary tangles49-50. 
Amyotrophic lateral sclerosis, a rapidly 
progressing motor neurone disease, is associated 
with mutation of superoxide dismutase (SOD1) 
gene, and mice that overexpress mutant SOD1 
show upregulation of TNF-alpha51, suggesting 
activation of microglia. Similarly, IL-1 levels are 
elevated in CSF of Creutzfeldt-Jakob disease (CJD) 
patients, and activated microglia are detected in 
mice infected with CJD52. 
In Parkinson's disease, cytokines from activated 
microglia in the substantia nigra and putamen were 
seen to be neurotoxic resulting in degeneration of 
dopamine neurons during the progress of the 
disease53.  
Recent investigation suggests a strong 
relationship between immunological effects and the 
pathophysiology of schizophrenia. Several 
cytokines, including IL-1β, IL-2, IL-6 and IFN, 
were found elevated in plasma of working-age 
adults with depression and dysthymia. Similar 
associations were reported between cytokines and 
late-life depression, with IL-1β, IL-6 and TNF-α 
elevation in both depression and dysthymia. 
Increased cytokine levels may also serve as an 
explanation for the increased risk for vascular 
disease that has been associated with 
depression54,55. 
 
Inflammation: Beneficial or Detrimental? 
Duality of the innate immune system 
The limitation of immune responsiveness in the 
mammalian CNS has been attributed to the intricate 
nature of neuronal networks, which would appear to 
be more susceptible than other tissues to the threat 
of permanent disorganization when exposed to 
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massive inflammation. This line of logic led to the 
conclusion that all forms of CNS inflammation 
would do more harm than good and, hence, the less 
immune intervention the better. However, mounting 
evidence indicates that some forms of immune-
system intervention can help to protect or restore 
CNS integrity56.  
In response to a brain insult, astrocytes become 
activated, increasing expression of glial fibrillary 
acidic protein, and producing cytokines; they also 
contribute to the formation of the glial scar, which 
isolates the damaged area, but also acts as a barrier 
to reinnervation. Prevention of this reactive 
astrogliosis might be predicted to be beneficial for 
repair and recovery, but in fact this increases 
neuronal loss from the injury site and inhibits repair 
of the BBB and axonal remyelination, partly 
because astrocytes produce neurotrophic factors 
such as nerve growth factor and brain-derived 
growth factor that are upregulated by injury57.  
Cytokines themselves may also have dual roles, 
with detrimental acute effects, but beneficial effects 
in the longer term. Both TNF-α and IL-1 are 
strongly implicated in neuronal loss during acute 
and chronic neurodegenerative disease, but also 
participate in repair and recovery. Although TNF-α 
is found associated with active MS lesions, induces 
death of oligodendrocytes, and increases disease 
severity in animal models of MS, blocking this 
cytokine in human clinical trials was not beneficial, 
and in fact, worsened the disease58. Furthermore, 
cytokine 'priming' or 'preconditioning' prior to 
disease onset can be beneficial. For example, 
pretreatment with IL-1 is neuroprotective against 
ischaemic injury, and reduced neurological deficits 
in an animal model of MS59.  
 
In conclusion, exploring these highly complicated 
pathophysiological mechanisms underlying tissue 
damage should be a research priority. Inflammatory 
pathways involving interleukin and cytokine 
signalling might suggest potential targets for 
intervention and development of novel therapies to 
circumvent synaptic and neuronal dysfunction 
ultimately leading to neuro-degeneration. 
 
 
 
Brain cytokines and Chemokines 
 
Fig.1. Schematic illustration of neuro-glio-vascular interaction in the ischemic brain. Ischemic or excitotoxic stress induces 
neuronal injury and thereby chemokine (e.g., MCP-1) production in astrocytes via neuro-glial interaction. Activation of a 
MEK/ERK cascade is crucial for the induction of MCP-1 in astrocytes. Fractalkine could be released from excited or 
damaged neurons in the ischemic brain. One possible site for the action of brain chemokines is microglia/macrophages 
expressing several types of chemokine receptors. Activated microglia and macrophages produce neurotoxic substances 
including nitric oxide and free radicals, and various types of chemokines such as IL-1 and TNF-α, which in turn act on 
astrocytes to produce additional chemokines probably via the activation of NFκB. Another possible target for chemokines is 
the vascular endothelium. Chemokines such as MCP-1, act on the endothelial cells to induce the extravasation of 
macrophages into the brain parenchyma. Permeability of the blood brain barrier (BBB) is also affected by chemokines. 
Increased permeability of the BBB leads to brain edema formation and parenchymal hemorrhage.  
                                                                                                  (Quoted from Minami et al, 2006)30  
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